A Multiple Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of SRK-001 in Healthy Participants

Healthy Participants Clinical Trial

Official title:

A Randomized, Placebo-Controlled, Double-blind, Multiple Dose, Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics Following Intravenous Administration of SRK-001 in Healthy Participants

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT05156034
• Other study ID #: SRKMD-2021
• Secondary ID: 2021-003991-15
• Status: Terminated
• Phase: Phase 1
• Start date: December 21, 2021
• Est. completion date: September 5, 2022

Study information

• Verified date: March 2023
• Source: Sarkana Pharma Inc
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of the study is to evaluate safety, tolerability, and pharmacokinetics (PK) of SRK-001 in Healthy Participants.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 16
• Est. completion date: September 5, 2022
• Est. primary completion date: September 5, 2022
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• Participants who have clinical chemistry laboratory values within the acceptable range for the population, as per the investigator judgment
• Body mass index of 18 to 32 kilogram (kg)/ square meter (m^2)
• Healthy male participants

1. Nonvasectomized male participants must agree to abstain from sexual intercourse or use a condom as well as 1 additional highly effective method of contraception (less than [<]1 percent [%] failure rate) or effective method of contraception with all sexual partners of childbearing potential during the study and for 90 days following the last dose of study intervention

2. Must agree not to donate sperm from start of dosing until 90 days beyond the last dose of study intervention

3. No restrictions are required for a vasectomized male

• Healthy female participants of childbearing potential who have a fertile male sexual partner must be willing and able to practice effective contraception from screening to 90 days after the last dose of the study intervention. Sexually active participants must use a combination of 2 of the following methods of contraception, including at

least 1 so-called 'barrier' method:

1. hormonal contraceptives (oral, transdermal patches, vaginal, or injectable)

2. intrauterine device with or without hormones

3. condom, diaphragm, or cervical cap ('barrier' method)

4. sexual abstinence, and

5. vasectomized partner

• Has been fully vaccinated for COVID-19 with the last dose of vaccine administered at least 3 weeks prior to study intervention administration

Exclusion Criteria:

• For at least 30 days prior to randomization, participants must have no symptoms and/or signs of confirmed or suspected infection (including COVID-19) and must have completed any appropriate anti-infective treatment
• Have any concomitant systemic disorder, human immunodeficiency virus (HIV) infection, current infection with hepatitis B virus (HBV) (that is, positive for hepatitis B surface antigen and/or polymerase chain reaction positive for HBV DNA, hepatitis C virus (HCV) (that is, positive for HCV ribo nucleic acid[RNA]), symptomatic herpes zoster within 6 months prior to screening, an eye condition currently requiring treatment for trauma, contact allergy, postsurgical, or conjunctivitis that may interfere with eye evaluations, active or latent tuberculosis (TB)
• Are currently enrolled in or have participated in greater than (>) 4 clinical trials in the past 12 months involving a study intervention or off-label use of a drug or device, or any other type of medical research judged not to be scientifically or medically compatible with this study or have received a. any nonbiologic IP within 30 days or 5 half-lives (whichever is longer) of their baseline (Day -1) visit, or b. any biologic IP within 3 months or 5 half-lives (whichever is longer) of their baseline (Day -1) visit
• Have an average weekly alcohol intake that exceeds 21 units per week (males) or 14 units per week (females) or are unwilling to stop alcohol consumption from 48 hours prior to each dosing (1 unit = 12 ounce [oz] or 360 milliliter [mL] of beer; 5 oz or 150 mL of wine; 1.5 oz or 45 mL of distilled spirits)
• Drug abuse in the past 12 months and/or show positive findings on drug screening unless they were prescribed by a physician (for example, benzodiazepines)

Related Conditions & MeSH terms

• Healthy Participants

Intervention

Drug:
• SRK-001
Participants will receive IV doses of SRK-001.
• Placebo
Participants will receive IV doses of placebo.

Locations

Country	Name	City	State
Netherlands	PRA Health Sciences	Groningen

Sponsors (1)

Lead Sponsor	Collaborator
Sarkana Pharma Inc

Country where clinical trial is conducted

Netherlands, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs)	Number of participants with one or more TEAEs and SAEs will be reported in the adverse events module.	Baseline through final follow-up at approximately Day 155
Secondary	Area Under the Concentration Versus Time Curve During a Dosing Interval (AUC0-tau) at Steady State	Pharmacokinetics (PK) after single and multiple IV dosing.	Day 1 (End of the infusion [EOI]) up to Day 155 post EOI
Secondary	Half-Life (t1/2)	PK after single and multiple IV dosing.	Day 1 (EOI) up to Day 155 post EOI
Secondary	Concentrations at End of Infusion (Cmax)	PK after single and multiple IV dosing.	Day 1 (EOI) up to Day 155 post EOI
Secondary	Concentrations at End of Dosing Interval (Ctrough)	PK after single and multiple IV dosing.	Day 1 (EOI) up to Day 155 post EOI